Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2018

Revenue From Contract With Customer [Abstract]

Disaggregated Revenues by Timing of Transfer of Goods or Services

The following table presents our revenues, disaggregated by timing of transfer of goods or services (in thousands):

	Three Months Ended March 31, 2018
	Product Revenue, net		Collaboration and License Revenue		Total
Timing of revenue recognition:
Transferred at a point in time	$	606	$	—	$	606
Transferred over time		—		6,038		6,038
Total	$	606	$	6,038	$	6,644

Schedule of Changes in Contract Assets and Liabilities

The following table presents changes in our contract assets and liabilities for the three months ended March 31, 2018 (in thousands):

	Balance at Beginning of Period		Addition		Deduction			Balance at End of Period
Contract assets:
Unbilled - collaboration and license revenue	$	6,694	$	2,761	$	(4,795	)	$	4,660
Total contract assets	$	6,694	$	2,761	$	(4,795	)	$	4,660
Contract liabilities:
Deferred revenue	$	7,623	$	5,173	$	(3,523	)	$	9,273
Total contract liabilities	$	7,623	$	5,173	$	(3,523	)	$	9,273

Estimated Revenue Expected to be Recognized in Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of March 31, 2018 (in thousands):

Collaborator	Transaction Price Allocated to the Remaining Performance Obligation as of March 31, 2018		Expected Year By Which Revenue Recognition Will Be Completed		Percentage of Revenue Recognized
BMS and Pfizer - 2014 agreement	$	909		2019		94	%
BMS and Pfizer - 2016 agreement		4,131		2021		73	%
Daiichi Sankyo - 2014 agreement		3,173		2019		91	%
Daiichi Sankyo - 2016 agreement		3,818		2021		69	%
Bayer and Janssen - 2014 agreement		1,420		2019		94	%
Bayer - 2016 agreement		3,389		2021		73	%
Total	$	16,840